Košík

0473109 - ÚMG 2017 RIV US eng J - Článek v odborném periodiku
Yong, K.J. - Basseres, D.S. - Welner, R.S. - Zhang, W.C. - Yang, H. - Yan, B. - Alberich-Jorda, Meritxell - Zhang, J. - de Figueiredo-Pontes, L.L. - Battelli, C. - Hetherington, C.J. - Ye, M. - Zhang, H. - Maroni, G. - O'Brien, K. - Magli, M.C. - Borczuk, A.C. - Varticovski, L. - Kocher, O. - Zhang, P. - Moon, Y.C. - Sydorenko, N. - Cao, L. - Davis, T.W. - Thakkar, B.M. - Soo, R.A. - Iwama, A. - Lim, B. - Halmos, B. - Neuberg, D. - Tenen, D.G. - Levantini, E.
Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBP alpha expression.
Science Translational Medicine. Roč. 8, č. 350 (2016), č. článku 350ra104. ISSN 1946-6234. E-ISSN 1946-6242
Grant CEP: GA MŠMT LK21307
Institucionální podpora: RVO:68378050
Klíčová slova: ccaat/enhancer-binding-protein * acute myeloid-leukemia * factor-c/ebp-alpha * posttranscriptional control * adjuvant chemotherapy * cell-proliferation * down-regulation * drug discovery * gene signature * self-renewal
Kód oboru RIV: EB - Genetika a molekulární biologie
Impakt faktor: 16.761, rok: 2016
Trvalý link: http://hdl.handle.net/11104/0270322